Michael O'Riordan is a Senior Journalist for TCTMD, specializing in the field of cardiology and cardiovascular research. With a focus on providing up-to-date and accurate information, Michael's articles cover a wide range of topics including clinical trials, treatment options, and emerging trends in the field of cardiology.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Michael O'Riordan's articles predominantly cite data and cover topics related to cardiovascular disease, medical research, treatment options, and risk factors. He would likely be receptive to pitches offering insights from experts in the healthcare and pharmaceutical industry who can provide informed perspectives on new research findings, treatment developments, or changes in medical guidelines related to cardiovascular diseases.
Given his focus on citing data extensively in his coverage, he may appreciate pitches that offer access to proprietary or exclusive datasets relevant to the topics he covers. Additionally, sources with a deep understanding of scientific methodologies and clinical trial design could capture Michael's interest.
While there is no specified geographic focus for Michael's work, his articles appear internationally focused based on the subjects covered.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Reimbursement doesn't currently cover costs of the test, but that could change if CMS ties payment to a cardiology revenue code.
A difference seen in CKD outcomes, however, might help clinicians trying to individualize treatment options, experts say.
By: Michael O Riordan
There is no need for alarm, say researchers, but the publicly reported data deserve further study.
By: Michael O Riordan
The study failed to show that stopping beta-blockers after MI was noninferior to continuing treatment, surprising researchers.
By: Michael O Riordan
There was a reduction in MACE with PCI before TAVI, but that doesn't mean revascularization should be the norm, say experts.
By: Michael O Riordan
Quickly cutting non-HDL cholesterol after MI lowers the risk of MACE compared with stepwise use of lipid-lowering therapy.
There was no reduction in CV death, but HF doctors are happy to gain another agent for use in HFmrEF/HFpEF patients.
By: Michael O Riordan
No impact was seen on mortality between the invasive and medical arms, but other endpoints may mean more to patients.
By: Michael O Riordan
The DynamX Bioadaptor device was noninferior to DES for TLF overall, but a landmark analysis reveals a potential strength.
The majority of FDA-recalled devices made it to market via the 510(k) pathway, which doesn't require new clinical or safety data.
(833) 317-6278 
